On September 30, Moderna, Inc. fell 3.18% in pre-market trading, trading at $197.65/share, with turnover of approximately $10.52 million.

Within the Biotechnology sector where Moderna, Inc. belongs, the overall sector movement is mixed. Among individual stocks, Natera up 0.8%, Amgen up 0.24%, AbbVie up 0.21%, Gilead Sciences up 0.01%, Iovance Biotherapeutics, Inc. down 0.97%.

Moderna, Inc. is a biotechnology company that discovers, develops, and commercializes messenger RNA therapeutics and vaccines. Its platform spans infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company has strategic collaborations with AstraZeneca, Merck, Vertex Pharmaceuticals, and others. The company is headquartered in Cambridge, Massachusetts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)